CN1319527C - Use of tea polyphenol for preparing medicine for preventing and treating lipsotrichia induced from chemotherapy - Google Patents
Use of tea polyphenol for preparing medicine for preventing and treating lipsotrichia induced from chemotherapy Download PDFInfo
- Publication number
- CN1319527C CN1319527C CNB2004100158986A CN200410015898A CN1319527C CN 1319527 C CN1319527 C CN 1319527C CN B2004100158986 A CNB2004100158986 A CN B2004100158986A CN 200410015898 A CN200410015898 A CN 200410015898A CN 1319527 C CN1319527 C CN 1319527C
- Authority
- CN
- China
- Prior art keywords
- egcg
- chemotherapy
- preventing
- day
- tea polyphenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to the use of tea polyphenol for preparing medicine or functional food for preventing and treating alopecia induced from chemotherapy. The tea polyphenol is an extract product of which the epi-gallo-catechin-gallate (EGCA) content is at least more than 30% or epigallocatechin gallate with a single ingredient, wherein the extract product or the epigallocatechin gallate contains a flavonol structure and is extracted from tea leaves. A result of animal tests shows that EGCG can obviously prevent loss of hair caused by CYP for a mouse. Therefore, EGCG has significant application values for clinically preventing and treating alopecia induced from chemotherapy medicine.
Description
Technical field
The present invention relates to drug world.Be specifically related to tea polyphenols and cause application in alopecia medicine or the functional food because of chemotherapy in preparation prevention and treatment.
Background technology
One of side reaction of the chemotherapeutics maximum of treatment tumor is exactly alopecia at present, and this causes very big physiology and psychological injury to patient, does not have medicine to treat so far.
Tea polyphenols is the active component that extracts from Folium Camelliae sinensis; mainly contain flavanol compound, flavonoid, anthocyan and phenolic acid compound; it is reported that it has antioxidation, antitumor, atherosclerosis, heart tonifying, arrhythmia, control cerebral ischemia reperfusion injury, anti-dental caries tooth protection, multiple pharmacological effect such as antibacterial, can be used for developing health food, resisting cardiovascular disease and antitumor medicine, anti-ultraviolet cosmetics, anti-dental caries toothpaste, natural food colour and food antioxidant etc.But do not see so far about using it for and prevent and treat the various medicines of the alopecia that causes because of chemotherapy and the report of functional food.
Summary of the invention
Technical problem to be solved by this invention is to develop the new purposes of tea polyphenols, provides tea polyphenols to cause application in alopecia medicine or the functional food because of chemotherapy in preparation prevention and treatment.
Tea polyphenols of the present invention is meant that the epigallocatechin gallate (EGCG) that contains the flavanol compound structure that extracts (Epi-gallo-catechin-gallate is called for short EGCG) content is at least at the epigallocatechin gallate (EGCG) of extract more than 30% or single component from Folium Camelliae sinensis.
The method that tea polyphenols of the present invention extracts from Folium Camelliae sinensis is the conventional tea polyphenol extracting method, promptly is raw material with Folium Camelliae sinensis, after Diluted Alcohol soaks, and heating extraction, extracting solution is used ethyl acetate extraction after reclaiming ethanol, and the extract concentrate drying is promptly.Adopt high-pressure liquid phase to detect the wherein content of EGCG, at least 30%.
Folium Camelliae sinensis is the leaf of plant of theaceae tea Camellia sinensis O.Ktze., and is cool in nature, and bitter in the mouth, sweet is raw-food material commonly used.The EGCG that is obtained by its extraction has following formula I structure:
The extremely strong removing of tea polyphenols tool is from the effect of trip base, and can microcirculation improvement, promote the improvement of blood circulation state, help keeping the stable of predicament in cell and the body, prevent the damage of hair follicle cell, this is that tea polyphenols can trichogenous main cause.
The present invention contains the tea polyphenols composite parts of epigallocatechin gallate (EGCG) (EGCG) more than 30% with extraction from Folium Camelliae sinensis and carries out about preventing and treat the test of pesticide effectiveness that causes alopecia because of chemotherapy, the result shows: EGCG can obviously suppress the mice alopecia that cyclophosphamide (CYP) causes, illustrates that the alopecia that EGCG causes at the clinical prevention chemotherapeutics has important use value.The embodiment of the invention 2 has further description to this.
The test of pesticide effectiveness shows, contain that the tea polyphenols extract of EGCG more than 30% can be used as prevention and treatment causes the medicine of alopecia or the functional food of auxiliary treatment because of chemotherapy of tumors, its using method is that chemotherapy begins to take in last week tea polyphenols (tea polyphenols of EGCG more than 30%), every day 3 times, each 300mg-900mg, serveing on for 5 weeks is a course of treatment, takes equally before the next chemotherapy.
The specific embodiment
Embodiment 1
I, preparation technology
Get 10 kilograms of Folium Camelliae sinensis coarse dry powders and add 5 times of amount 50% soak with ethanol 12 hours, heating extraction 2 hours is filtered, and decompression filtrate recycling ethanol, water liquid add the moderate ethyl acetate extraction 2 times; The combined ethyl acetate extract, with washing in right amount, the ethyl acetate in the reclaim under reduced pressure extract, residue water dissolution to the relative density of heating is the concentrated solution of 1.08-1.09, concentrated solution carries out spray drying, about 120 grams of brown ceramic powder.
II, EGCG assay
1. checkout equipment
(HPLC) high performance liquid chromatogram equipment, day island proper Tianjin, place of production company
2. testing conditions
30 ℃ of temperature, wavelength: 280nm, liquid speed 1.0ml/min
Mobile phase liquid: use methanol: water: phosphoric acid, 27: 78: 0.1
Sample size: 10 μ l
3. computational methods
Peak area normalizing computational methods (standard specimen is provided by U.S. Xi Ge Man)
4. result
It is 55% that the said extracted thing records EGCG content.
Embodiment 2 animal experiments
1. experiment medicine
EGCG, purity is (embodiment 1 obtains) more than 55%, uses dissolved in distilled water before the use.
Cyclophosphamide (cyclophosphamide, CYP, injection), the pharmacy of Hua Lian, Shanghai has
Limit company, lot number is 030501, faces with before being dissolved in distilled water.
2. laboratory animal
Inbred line C57BL/6 female mice, in age (adolescence) in 6-8 week, 15-20g is by last
The western pul in sea-Bi Kai laboratory animal company limited provides.Mice is fed under normal operation, promptly
The receptacle temperature is 18-20 ℃, and illumination and dark each 12h hocket, and mice can be certainly
By feed and drinking-water.All experiment mices all are in the hair growth amortization period.Animal is grouped into: normal group, matched group, EGCG low dose group, EGCG high dose group, every group of 15 mices.
3. experimental technique
(1) the VI stage the anagen of inducing
With mouse anesthesia, coat fused Cera Flava and rosiny mixture with pentobarbital sodium (80mg/kg), after the hardening, peel off, make all hair follicles all be in early growth period at mouse back.During to 8-9 days, hair growth promptly enters the VI stage of early growth period, this moment the hair follicle development maturation, skin color is by grey blackening, and black hair bar newborn, homogeneous occurs.
(2) the alopecia experimental animal model be established to the 9th day the time, give matched group and EGCG group mice disposable celiac injection cyclophosphamide, injected dose is 100mg/kg, the normal group mice is only injected distilled water.
(3) dosage regimen
Until the 15th day, give the oral EGCG of mice from the back beginning in the 3rd day of losing hair or feathers, low dose group is 300mg/kg.d, and high dose group is 600mg/kg.d, irritates stomach (early, evening respectively once) at twice.
(4) the depilation situation of depilation back the 13rd day (behind the injection CYP the 4th day) and the 20th day (inject CYP after the 11st day):
The injection CYP after the 4th day, with mouse anesthesia, with unified resolution (1024 * 768, SONY DSC-P30 digital camera) take pictures for every mice of each group, utilize image analysis system (multiple day FR-988) comparison film to analyze, the whole depilation zone at selected back and a zone that does not obviously have mao bar to grow, measure its area respectively, and calculate the depilation area ratio of every mice: the area in whole depilation zone, depilation area ratio=the do not have mao area/back of bar growth district) * 100%.Add up the depilation area ratio of every group of mice, represent (x ± s), adopt t check carrying out statistical analysis with mean+SD.
4. experimental result
From losing hair or feathers back the 3rd day, skin engenders pigmentation, and color begins to become ash, and during to the 5th day, entire back all becomes Lycoperdon polymorphum Vitt and more smooth.During to 7-8 days, short and sparse hair bar has appearred in the spinal column both sides of the first half at back.
To depilation the last the 10th day, promptly to inject behind the CYP second day, the hair bar that promptly visible control group mice back grows has obviously and comes off, the regional skin that comes off reverts to more slick state again, color still is a Lycoperdon polymorphum Vitt, and EGCG high and low dose group is hairiness bar obscission also, but degree is lighter.To depilation back the 13rd day the time, promptly to inject behind the CYP the 4th day, matched group and EGCG group depilation phenomenon are more serious, but visible notable difference the results are shown in Table 1.
During to the 20th day, promptly injected behind the CYP the 4th day, hair recovers regeneration gradually, and each group depilation area ratio all obviously dwindles, but the depilation area ratio of matched group is still organized apparently higher than EGCG.The results are shown in Table 1.
Table 1EGCG causes the influence of the area of mice depilation to CYP
| Grouping | Number of animals (only) | Dosage regimen | The 13rd day the depilation area ratio (%) in depilation back | The 20th day the depilation area ratio (%) in depilation back |
| Normal group matched group EGCG low dosage EGCG high dose | 15 15 15 15 | Distilled water CYP+ distilled water CYP+EGCG (300mg/kg.d) CYP+EGCG (600mg/kg.d) | 10.26±4.11 ** 88.42±18.36 52.47±14.62 ** 42.55±12.97 ** | 3.13±1.41 ** 39.72±11.34 27.85±8.28 ** 21.26±6.55 ** |
*Compare P＜0.01 with matched group
5. conclusion
Employed CYP causes the animal model of mice alopecia in this experiment, has simulated the alopecia side effect that chemotherapeutics clinically causes.Experimental result shows that EGCG can obviously suppress the mice alopecia that CYP causes, illustrates that the alopecia that EGCG causes at the clinical prevention chemotherapeutics has important use value.
Claims (1)
1, epigallocatechin gallate (EGCG) causes the medicine of alopecia or the application in the functional food in preparation prevention and treatment because of chemotherapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100158986A CN1319527C (en) | 2004-01-17 | 2004-01-17 | Use of tea polyphenol for preparing medicine for preventing and treating lipsotrichia induced from chemotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100158986A CN1319527C (en) | 2004-01-17 | 2004-01-17 | Use of tea polyphenol for preparing medicine for preventing and treating lipsotrichia induced from chemotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1640393A CN1640393A (en) | 2005-07-20 |
| CN1319527C true CN1319527C (en) | 2007-06-06 |
Family
ID=34868134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100158986A Expired - Fee Related CN1319527C (en) | 2004-01-17 | 2004-01-17 | Use of tea polyphenol for preparing medicine for preventing and treating lipsotrichia induced from chemotherapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1319527C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816718A (en) * | 2016-04-27 | 2016-08-03 | 王沛 | External traditional Chinese medicine composition with hair care and hair blackening effects |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1178467A (en) * | 1995-03-14 | 1998-04-08 | 因迪纳有限公司 | Polyphenol fractions of tea, the use thereof and formulations containing same |
-
2004
- 2004-01-17 CN CNB2004100158986A patent/CN1319527C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1178467A (en) * | 1995-03-14 | 1998-04-08 | 因迪纳有限公司 | Polyphenol fractions of tea, the use thereof and formulations containing same |
Non-Patent Citations (3)
| Title |
|---|
| 自由基-功过是非细评说 孙海金，中国中医药报 2003 * |
| 辅助治疗药物和化疗药物 仲兆金，首都医药，第13期 2003 * |
| 辅助治疗药物和化疗药物 仲兆金，首都医药，第13期 2003;自由基-功过是非细评说 孙海金，中国中医药报 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1640393A (en) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101829553B1 (en) | Cosmetic composition comprising mixture extract of Pisum sativum, Scutellaria baicalensis, Ulmus davidiana, Hippophae rhamnoides fruit for improvement of skin damage or skin-protection | |
| CN114376952B (en) | Paeonia lactiflora extract and preparation method and application thereof | |
| EP1679060A1 (en) | Hair growth stimulant composition | |
| JPH1095735A (en) | Hyaluronic acid productivity potentiator | |
| KR20190064580A (en) | Use of ginseng extract and its active ingredient in promoting skin care and / or wound healing | |
| WO2018026103A1 (en) | Composition for cell regeneration comprising ginseng floral axis extract | |
| WO2018190501A1 (en) | Anti-inflammatory composition containing extract of ginseng flower stalk | |
| CN1319527C (en) | Use of tea polyphenol for preparing medicine for preventing and treating lipsotrichia induced from chemotherapy | |
| KR20190010482A (en) | Phlorotannin composition having inhibitory effect on induction of gray hair and promoting effect on induction of dark hair | |
| JP2002128657A (en) | Bleaching cosmetic | |
| CN113101253A (en) | Cosmetic composition for improving skin comprising mixed extract of edible flowers | |
| JP7338842B2 (en) | wrinkle-improving composition and wrinkle-improving skin cosmetic | |
| JP6799365B2 (en) | Cosmetic composition, cosmetological composition, joint protection composition, composition | |
| CN100335073C (en) | Process for preparing semen momordicae seed extract containing triterpene saponin component | |
| CN115969754A (en) | Composition with skin repairing effect | |
| KR20150145704A (en) | Composition comprising extract of autumn soybean-leaves | |
| KR20150081221A (en) | Cosmetic composition for improving anti-wrinkle containing the extract mori radicis cortex, Lindera obtusiloba and Lespedeza cuneata | |
| KR20100087825A (en) | Hangover curing agent containing taurine and flavonoid | |
| CN112451559A (en) | Use of flos Puerariae Lobatae extract in preventing and treating oxidative damage | |
| US20120251470A1 (en) | Method for extracting a traditional herbal medicine component using a polished-rice steaming method | |
| KR100670238B1 (en) | Skin anti-wrinkle cosmetics composite containing oriental herb extract and manufacturing method thereof | |
| CN1207047C (en) | Complex plant estrogen formulation which can delay female senility and method preparing same | |
| KR100841276B1 (en) | Skin Whitening Composition Containing Ethyl Acetate Fraction of White Ginseng with High Whitening Activity | |
| KR101801876B1 (en) | Chondroprotective agent containing impressic acid or derivatives thereof, or Acanthopanax koreanum leaf extract comprising the same | |
| WO2023149766A1 (en) | Cosmetic composition comprising saffron flower extract and danshen extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070606 Termination date: 20100219 |